-
公开(公告)号：US20240060988A1
公开(公告)日：2024-02-22
申请号：US18278571
申请日：2022-02-24
发明人： Rajiv Pranesh BHARADWAJ , Murali JAYARAMAN , Sakthi CHANDINI D , Aishwarya NATARAJAN , Aakash CHANDRAMOULI
CPC分类号： G01N33/6854 , C07K16/244 , G01N2440/36 , G01N2440/34 , C07K2317/41
摘要： The free thiol group present in free cysteines in recombinant therapeutic antibodies are reactive to process components and generates product variants during early stages of biosimilar development. Free thiol group present on the structural motifs, especially in the complementary determining regions (CDR), support maximal antigen binding capability. Product variants associated with these free thiol groups are detrimental for safety and efficacy of these therapeutic antibodies. Methods to identify and characterize various thiol variants an antibody composition is provided and an anti-IL-17A IgG1 composition having these thiol variants are described.
-
公开(公告)号：US20230391828A1
公开(公告)日：2023-12-07
申请号：US18030470
申请日：2021-10-06
IPC分类号： C07K14/00 , A61K47/60 , C07K14/435 , G01N33/68
CPC分类号： C07K14/001 , A61K47/60 , C07K14/435 , G01N33/6872 , G01N2440/36 , G01N2333/9015 , A61K38/00
摘要： The present invention relates to peptides and peptidomimetics as well as their medical use in the treatment of hyperproliferative diseases and inflammatory diseases.
-
公开(公告)号：US20230184745A1
公开(公告)日：2023-06-15
申请号：US17926668
申请日：2021-06-18
CPC分类号： G01N33/5035 , C12N9/104 , C07K14/70521 , C07K14/70532 , C07K14/522 , C07K14/71 , C07K16/28 , C07K16/40 , C07K2317/31 , C07K2317/569 , G01N2333/9015 , G01N2440/36 , C07K2319/40
摘要： The invention pertains to a method to identify an effective combination of a transmembrane E3 ubiquitin ligase and a membrane-bound protein, wherein the combination is effective when the transmembrane E3 ubiquitin ligase is capable of decreasing the surface level of the membrane-bound protein upon forced dimerization, preferably by ubiquitination of the membrane-bound protein. The method of the invention comprises a step of exposing a cell to a heterobifunctional molecule, wherein the heterobifunctional molecule comprises a first binding domain capable of specific binding to an extracellular portion of the transmembrane E3 ubiquitin ligase, and a second binding domain capable of specific binding to an extracellular portion of the membrane-bound protein. The method further comprises a step of determining the decrease in surface level of the membrane-bound protein. The invention additionally pertains to a heterobifunctional molecule targeting an effective combination of a transmembrane E3 ubiquitin ligase and a membrane-bound protein.
-
公开(公告)号：US09766241B2
公开(公告)日：2017-09-19
申请号：US14655744
申请日：2013-12-26
申请人： Toshihiro Nakajima
IPC分类号： G01N33/53 , G01N33/573 , G01N33/68 , G01N33/50 , C12Q1/68
CPC分类号： G01N33/573 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/5044 , G01N33/6875 , G01N2333/70567 , G01N2333/9015 , G01N2440/36 , G01N2500/04 , G01N2500/10
摘要： [Problem]To provide a mitochondria-function regulator effective for treatment or prevention of obesity, and a screening method therefore.[Solution]The mitochondria-function regulator of the present invention contains, as an active ingredient, a PGC-1β-protein function regulator synoviolin. The screening method of the present invention includes a step for causing a test substance to act on an adipose tissue cell or an individual animal, and measuring or detecting one or more of the following in the adipose tissue cell: (1) expression level of synoviolin; (2) a bond between synoviolin and PGC-1β protein; and (3) the ubiquitination of the PGC-1β protein by synoviolin.
-
公开(公告)号：US09556262B2
公开(公告)日：2017-01-31
申请号：US14627597
申请日：2015-02-20
申请人： Genentech, Inc.
CPC分类号： C07K16/18 , C07K14/4702 , C07K2317/24 , C07K2317/30 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C12N15/1037 , G01N33/68 , G01N2333/4703 , G01N2440/36
摘要： The invention provides anti-polyubiquitin antibodies and methods of using the same.
摘要翻译： 本发明提供抗多聚遍在蛋白抗体及其使用方法。
-
6.发明授权Method for determining depression, kit for analyzing serotonin transporter, and kit for analyzing ubiquitinated serotonin transporter in blood 有权用于测定抑郁症的方法，用于分析血清素转运蛋白的试剂盒和用于分析血液中的泛素化血清素转运蛋白的试剂盒公开(公告)号：US09274127B2
公开(公告)日：2016-03-01
申请号：US14233374
申请日：2012-07-19
申请人： Toshitaka Nabeshima , Akihiro Mouri
发明人： Toshitaka Nabeshima , Akihiro Mouri
CPC分类号： G01N33/942 , C12Q1/6881 , G01N33/6896 , G01N2333/4703 , G01N2440/36 , G01N2800/304
摘要： [Problem] To provide: a method for utilizing a novel marker, including a method for determining depression; and a kit for analyzing an ubiquitinated serotonin transporter.[Solution] A method for determining depression, comprising a step of analyzing the proportion of an ubiquitinated serotonin transporter in a blood sample collected from a subject; and a kit for analyzing an ubiquitinated serotonin transporter in blood, which comprises an ubiquitinated protein collector material and an anti-serotonin transporter antibody and is used for the analysis of the proportion of an ubiquitinated serotonin transporter in a collected blood sample.
摘要翻译： [问题]提供：一种利用新型标记的方法，包括用于确定抑郁症的方法; 以及用于分析泛素化的5-羟色胺转运蛋白的试剂盒。 [解决方案]一种用于测定抑郁症的方法，包括分析从受试者收集的血液样品中的遍在蛋白化的5-羟色胺转运蛋白的比例的步骤; 以及用于分析血液中泛素化的血清素转运蛋白的试剂盒，其包含泛素化的蛋白质收集剂材料和抗5-羟色胺转运蛋白抗体，并用于分析收集的血液样品中普遍存在的5-羟色胺转运蛋白的比例。
-
7.发明申请DIAGNOSTIC METHOD BASED ON LARGE SCALE IDENTIFICATION OF POST-TRANSLATIONAL MODIFICATION OF PROTEINS 审中-公开基于大规模鉴定蛋白质翻译后修饰的诊断方法公开(公告)号：US20150309044A1
公开(公告)日：2015-10-29
申请号：US14796408
申请日：2015-07-10
发明人： Yifat Merbl , Marc W. Kirschner
IPC分类号： G01N33/68
CPC分类号： G01N33/6845 , G01N33/57484 , G01N33/6842 , G01N2440/00 , G01N2440/14 , G01N2440/36 , G01N2800/00 , G01N2800/28 , G01N2800/2821 , G01N2800/2835
摘要： Methods for the large scale identification of post-translational modification states of proteins and enzyme activities for carrying out post-translational modification reactions involve the analysis of functional extracts from fresh and frozen samples using protein arrays. The methods and kits of the present invention can be used to analyze and characterize compounds for their effects on post-translational modifications and their pathways. The methods and kits can also be used to diagnose and characterize a wide variety of diseases and medical conditions, including cancer, neurodegenerative diseases, immune diseases, infectious diseases, genetic diseases, metabolic conditions, and drug effects using cells or body fluids of a patient.
摘要翻译： 用于进行翻译后修饰反应的大规模鉴定蛋白质和酶活性的翻译后修饰状态的方法涉及使用蛋白质阵列分析来自新鲜和冷冻样品的功能提取物。 本发明的方法和试剂盒可用于分析和表征化合物对其翻译后修饰及其途径的影响。 方法和试剂盒还可用于诊断和表征各种疾病和医学状况，包括癌症，神经变性疾病，免疫疾病，传染病，遗传疾病，代谢状况和使用患者的细胞或体液的药物作用 。
-
8.发明申请Catalytic Tagging System to Study Macro-Molecular Interactions Using Engineered Ubiquitin Ligase and Ubiquitin-Like Proteins to Facilitate Substrate Identification 审中-公开催化标记系统研究使用工程化泛素连接酶和泛素类蛋白质的宏观分子相互作用，以促进底物鉴定公开(公告)号：US20150010525A1
公开(公告)日：2015-01-08
申请号：US14371533
申请日：2013-01-23
发明人： James A. Wells , Min Zhuang
CPC分类号： G01N33/6848 , C07K2319/00 , C07K2319/95 , C12N9/16 , C12N9/93 , C12Q1/25 , C12Y301/03016 , C12Y603/02 , C12Y603/02019 , G01N33/58 , G01N33/94 , G01N2440/36 , G01N2458/15 , G01N2500/00 , G01N2500/02 , G01N2500/10
摘要： The present invention describes an unbiased catalytic tagging system to search for target substrates. Identification of substrates for specific baits is accomplished by utilizing an orthogonal system consisting of an E1 activating enzyme, an E2 ubiquitin-like conjugating enzyme, and baits that are fused to the E2 ubiquitin-like conjugating enzyme. The present invention thus reveals important mutually antagonistic substrates of specific baits.
摘要翻译： 本发明描述了一种用于搜索目标基底的无偏差的催化标记系统。 通过利用由E1活化酶，E2泛素样结合酶和与泛素类共轭酶融合的诱饵组成的正交系统来确定特定诱饵的底物。 因此，本发明揭示了特定诱饵的重要的相互拮抗的底物。
-
公开(公告)号：US20140179593A1
公开(公告)日：2014-06-26
申请号：US14118132
申请日：2012-05-16
IPC分类号： C07K14/47 , G01N33/566
CPC分类号： C07K14/47 , A61K38/00 , C07K2299/00 , C12N9/93 , C12Y603/02019 , G01N33/566 , G01N33/573 , G01N2333/9015 , G01N2440/36 , G01N2500/04
摘要： Provided herein is a novel binding pocket within NEDD8 co-E3 proteins that binds NEDD8 E2 enzymes. Particularly at its M-Terminus. Methods are provided for screening for compounds that bind to the disclosed E2-binding pocket in NEDD8 co-E3 proteins. Compounds that bind to the E2-binding pocket and optionally inhibit the activity of NEDD8 co-E3 proteins and pharmaceutical compositions comprising the same are further provided. The NEDD8 co-E3 inhibitors find use, as agents preventing the NEDDylation of a target protein, in inhibiting cell growth and methods for treating cancers, inflammatory disorders, and pathogenic infections. The preferred inhibitors are peptides corresponding to a M-terminal fragment of Dnc1, e.g. MTLASKLKRDD, MLKLRQLQKKKQ, and MIKLFSLKQQKK, which are substituted at the M-Terminus with an uncharged group (e.g. acyl).
摘要翻译： 本文提供了结合NEDD8 E2酶的NEDD8 co-E3蛋白内的新结合口袋。 特别是在其M-Terminus。 提供了用于筛选与NEDD8共-E3蛋白中公开的E2结合口袋结合的化合物的方法。 还提供结合E2结合口袋并任选地抑制NEDD8共-E3蛋白的活性的化合物和包含其的药物组合物。 NEDD8 co-E3抑制剂用作抑制靶蛋白的NEDD化作为抑制细胞生长的药剂以及用于治疗癌症，炎性疾病和致病性感染的方法。 优选的抑制剂是对应于Dnc1的M末端片段的肽，例如 MTLASKLKRDD，MLKLRQLQKKKQ和MIKLFSLKQQKK，它们在不带电荷的基团（例如酰基）的M-Terminus取代。
-
公开(公告)号：US20140134644A1
公开(公告)日：2014-05-15
申请号：US14078020
申请日：2013-11-12
发明人： Denise L. FAUSTMAN
IPC分类号： G01N33/543
CPC分类号： G01N33/564 , G01N2333/912 , G01N2440/14 , G01N2440/36 , G01N2800/101
摘要： The invention features methods and kits for determining the presence of, or a predisposition to develop, Sjögren's syndrome in humans. The invention features methods to detect changes in the levels of one or more LMP-2 protein isoforms, in particular phosphorylated isoforms of LMP-2, and to detect changes in cellular protein phosphorylation and ubiquitination in samples from Sjögren's patients.
摘要翻译： 本发明的特征在于确定人类Sjögren综合征的存在或发生倾向的方法和试剂盒。 本发明的特征在于检测一种或多种LMP-2蛋白质异构体（特别是LMP-2的磷酸化同种型）的水平变化的方法，并检测Sjögren患者样品中细胞蛋白磷酸化和泛素化的变化。
-
-
-
-
-
-
-
-
-
搜索结果
72 条记录 (耗时 0.042 秒)
